Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of palifosfamide-tris with doxorubicin for soft tissue sarcoma (PICASSO 111)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This study was looking at a drug called palifosfamide-tris alongside doxorubicin for soft tissue sarcoma.
Sadly this treatment does not work for everyone. Doctors wanted to see if having a drug called palifosfamide-tris alongside doxorubicin worked better then doxorubicin alone.
Palifosfamide-tris works by sticking together the cancer cell’s DNA so that it can't come apart again. This means that the cell can't reproduce itself.
The aim of this study was to find out if doxorubicin and palifosfamide-tris together was better at treating soft tissue sarcoma that had spread than doxorubicin alone.
Summary of results
The trial was stopped early because results showed that people who took palifosfamide-tris weren't living without signs of their sarcoma getting worse for any longer than the people who had doxorubicin alone.
How to join a clinical trial
Professor Ian Judson
National Institute for Health Research Cancer Research Network (NCRN)
Ziopharm oncology Inc